for the most common viruses known to cause myocarditis (cocksackievirus, parvovirus B19, human herpesvirus 6 and other adeno-/enteroviridae), viral serologies from peripheral blood were negative in all patients [2] . Myocardial biopsies typically show lymphocytic infiltrates with predominance of cytotoxic CD8 T cells and decreased FoxP3+ regulatory Tcells. While endomyocardial biopsy remains the gold standard for the definitive diagnosis of myocarditis, its use is recommended in: 1) Heart failure requiring inotropic or mechanical circulatory support, 2) Mobitz type 2 second degree or higher heart block, 3) sustained or symptomatic ventricular tachycardia or 4) failure to respond to guideline based medical management within 1-2 weeks (class of recommendation I, level of evidence B) . Cardiac MRI may is a valuable noninvasive alternative, if myocarditis is suspected [5] . For general surveillance during CPI treatment, we recommend a physical exam, routine laboratory parameters including troponin, and ECG in regular intervals (every 1-2 months). An echocardiogram at baseline should be obtained and repeated if there is a change in clinical status suggesting compromised cardiovascular function. In that scenario, a cardiac MRI may be considered as well.
In the event of increasing troponin levels, Wang and colleagues recommend to hold immunotherapy [6] . In a symptomatic patient with myocarditis, immunotherapy has to be stopped with subsequent initiation of high dose steroid treatment. In that scenario, endomyocardial biopsy may be considered to obtain a definitive diagnosis of myocarditis.
While these conclusions and recommendations reflect our interpretation of findings from case reports and case series, no guidelines for the treatment of immune related myocarditis have been published as of today due to limited availability of clinical data.
Assuming an immune antigen reaction similar to an allograft rejection or a rheumatic disease, similar pathomechanisms have to be explored to widen treatment options for this rare but often fatal complication. In one reported case of CPI related and steroid resistant myocarditis, treatment with equine anti-thymocyte globulin (ATGAM) led to regression of the disease [7] . Similar to cases of allograft dysfunction, additional immunosuppressive therapy with mycophenolate mofetil or calcineurin inhibitors may be beneficial. The histopathological findings of increased effector T cells and decreased regulatory T cells in patients with immune related adverse events suggests an imbalance of inflammatory and anti-inflammatory T cell subsets. This mimics the setting of chronic graft dysfunction in which upregulation of regulatory T cells to restore balance has been shown to decrease inflammation and reduce tissue damage [8] . Similar to auto-immune myocarditis in sarcoidosis, vasculitic disease, or lupus anti-rheumatic agents such as TNFalpha inhibitors or cyclophosphamide may be considered. Studies in animal models are necessary to elucidate the immunologic pathways and cross reactivities causing these adverse events. Meanwhile, caregivers should be aware of the classic risk factors for cardiotoxicity under CPI treatment: Hypertension, decreased left ventricular function, rhythm abnormalities, an predisposition to autoimmune disease. In challenging clinical scenarios with presence of several of these risk factors, an interdisciplinary approach as well as sharing of data of incidence and outcome with the scientific community is invaluable to make future immune therapy both safer and more efficient.
